Orthofix presents long-term evidence of cervical disc arthroplasty effectiveness
70,000 M6-C discs have been implanted in over 20 countries
LEWISVILLE, Texas, Oct 10: Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, has announced the presentation of long-term evidence highlighting the clinical management of cervical disc arthroplasty during the North American Spine Society (NASS) 2022 annual meeting October 12-15 in Chicago.
Orthofix M6-C Artificial Cervical Disc.
“We are pleased to sponsor the presentation of data supporting the clinical effectiveness of cervical disc arthroplasty including five-year data from our US IDE study,” said Kevin Kenny, Global President of Orthofix Spine. “We are honored to have a distinguished surgeon panel that will provide their insights about cervical disc replacement and long-term outcomes of this therapy for patients suffering from degenerative disc disease.”
Presentation
The presentation will be conducted on Wednesday, Oct. 12 at 12:00 pm in the Red Theater located in the Exhibit Hall by Dr. Armen Khachatryan, Dr. Frank Phillips, Dr. Josh Jacobs, Steve Kurtz, Ph.D., and Gunnar Andersson, Ph.D.
Highlights that will be presented include:
The M6-C artificial cervical disc is designed to maintain the natural behavior of a functional spinal unit by replicating the biomechanical characteristics of the native disc. The disc was first commercialized outside of the United States in 2006 and was approved by the US Food and Drug Administration in 2019. To date, more than 70,000 M6-C discs have been implanted in over 20 countries, with 20 percent of these discs having been implanted for more than 10 years. The M6-C disc has a 0.7 percent worldwide complaint rate for all M6-C discs implanted to date.
Results of a Kaplan Meier analysis of the M6-C artificial cervical disc based on 16 years of real-world evidence suggest a global cumulative survivorship (percentage of implanted devices that are still intact and functional at a specific time period) of 99% at 10 years, consistent with other, proven, joint-arthroplasty devices such as hip and knee replacements.
Orthofix Medical Inc. is a global medical device company with a spine and orthopedics focus. The Company’s mission is to deliver innovative, qualitydriven solutions while partnering with health care professionals to improve patient mobility. Headquartered in Lewisville, Texas, Orthofix’s spine and orthopedics products are distributed in more than 60 countries via the Company’s sales representatives and distributors.
NEW YORK: Gayl Jones’ “The Birdcatcher,” a short, lyrical novel about a writer’s trip to Ibiza and the gifted, unstable couple she stays with, is a National Book Award finalist for fiction.
The nonprofit National Book Foundation has announced five finalists in each of five competitive categories - fiction, nonfiction, poetry, young people’s literature and translated books - winnowed from the 10 longlisted last month.
Nominees include the activist and former Olympics gold medalist
Tommie Smith, a young people’s literature nominee for “Victory. Stand!: Raising My Fist for Justice,” co-authored with Derrick Barnes and Dawud Anyabwile. Sharon Olds, whose previous honors include the Pulitzer Prize and the National Book Critics Circle award, is a poetry finalist for “Balladz,” and “His Name Is George Floyd,” by Robert Samuels and Toluse Olorunnipa, is a nonfiction nominee.
Jones, author of the acclaimed “Corregidora” and six other previous works of fiction, is the most established writer in a category that features three debut novels.
Nominees for translated books include the 2018 winners, Japanese author Yoko Tawada and translator Margaret Mitsutani, for the novel “Scattered All Over the Earth.”
Winners, each receiving $10,000, will be announced Nov 16 during a dinner benefit in Manhattan, in person for the first time since the coronavirus pandemic began. The previously announced honorary prizes will be presented to cartoonist Art Spiegelman and Tracie D. Hall, the executive director of the American Library Association.
Each category’s nominees are selected by panels of five, with judges including authors, editors, booksellers and other members of the literary community. Altogether, publishers submitted 1,772 works, including 607 nonfiction books and 463 fiction books.
Out of the 25 books nominated, 10 were released by Penguin Random House - the country’s largest trade publisher - and one by Simon & Schuster, which Penguin is attempting to buy. The
US Department of Justice has sued to block the merger, alleging the new company would reduce competition and drive down author advances. A judge’s decision is expected this fall.
Fiction nominees besides “The Birdcatcher” include three literary debuts: Tess Gunty’s “The Rabbit Hutch,” Sarah Thankam Mathews’ “All This Could Be Different” and Alejandro Varela’s “The Town of Babylon.” Jamil Jan Kochai is a finalist for his second book of fiction, “The Haunting of Hajji Hotak and Other Stories.”
In nonfiction, finalists along with “My Name is George Floyd” are Meghan O’Rourke’s “The Invisible Kingdom: Reimagining Chronic Illness,” Imani Perry’s “South to America: A Journey Below the Mason-Dixon to Understand the Soul of a Nation,”
David Quammen’s “Breathless: The Scientific Race to Defeat a Deadly Virus” and Ingrid Rojas Contreras’ memoir “The Man Who Could Move Clouds.”
In addition to “Victory. Stand!: Raising My Fist for Justice,” young people’s literature finalists include Kelly Barnhill’s “The Ogress and the Orphans,” Sonora
Reyes’s “The ...Guide to Catholic School,” Sabaa Tahir’s “All My Rage” and Lisa Yee’s “Maizy Chen’s Last Chance.”
Poetry finalists besides “Balladz” are Allison Adelle Hedge Coke’s “Look at This Blue,” John Keene’s “Punks,” Roger Reeves’ “Best Barbarian” and Jenny Xie’s “The Rupture Tense.” (AP)